Adaptive Biotechnologies Stock Price, News & Analysis

Adaptive Biotechnologies (NASDAQ: ADPT) announced two non-exclusive agreements with Pfizer on Dec 15, 2025: a target discovery collaboration to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis (RA) using Pfizer clinical samples, and a data licensing deal giving Pfizer access to Adaptive’s TCR-antigen datasets for AI/ML model training across immunology programs.

Adaptive will lead RA target discovery while Pfizer handles development and commercialization. Adaptive will receive an upfront payment and may earn additional milestone and licensing fees, with RA-related milestones potentially totaling about $890 million; specific financial terms are not disclosed.

Adaptive Biotechnologies (Nasdaq: ADPT) announced that Dr. Harlan Robins, Chief Scientific Officer and Co‑Founder, and Susan Bobulsky, Chief Commercial Officer, MRD, will participate in a Jefferies fireside chat on Minimal Residual Disease (MRD) in hematology/oncology with a deep dive into the clonoSEQ assay technology.

The session is scheduled for Thursday, December 11, 2025, 2:00 p.m. to 3:00 p.m. ET. Interested parties may contact their Jefferies sales representative for participation details.

Adaptive Biotechnologies (Nasdaq: ADPT) announced expanded clinical use of its clonoSEQ measurable residual disease (MRD) test at the 67th ASH Annual Meeting, Dec 6–9, 2025 in Orlando.

Key highlights: 90 abstracts feature clonoSEQ data, including 17 showing MRD-guided clinical interventions. The phase II EndRAD study reported that 51 NGS MRD-negative B-ALL patients receiving non-TBI transplant conditioning had outstanding event-free and overall survival comparable to standard TBI approaches. Additional data include 200-patient AURIGA MRD dynamics, intensified maintenance doubling MRD-negativity, and an 80-patient CLL cohort showing deep remissions at a 10^-6 MRD threshold.

Adaptive Biotechnologies (Nasdaq: ADPT) announced that its next-generation sequencing clonoSEQ® MRD test is featured in 89 abstracts, including 36 oral presentations, at the 67th ASH Annual Meeting scheduled for Dec. 6–9, 2025 in Orlando.

Abstracts cover multiple myeloma, ALL, CLL, MCL, DLBCL and other blood cancers, with more than 17 presentations showing clonoSEQ informing real-world treatment decisions and expanded use in clinical trials across modalities such as CAR T and bispecific antibodies.

Adaptive Biotechnologies (Nasdaq: ADPT) will participate in two investor conferences in late 2025: a presentation at the Jefferies Global Healthcare Conference in London on November 19, 2025 at 8:00 a.m. GMT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 8:30 a.m. ET.

Interested parties may access live and archived webcasts on the company’s Investors section at www.adaptivebiotech.com.

Adaptive Biotechnologies (Nasdaq: ADPT) reported third quarter 2025 results on November 5, 2025, showing strong MRD momentum and updated guidance.

Key points: Q3 revenue $94.0M (includes $33.7M one-time Genentech amortization); excluding Genentech $60.2M (+40% YoY). MRD revenue $56.8M (+52% YoY) with clonoSEQ volume 27,111 (+38% YoY). MRD achieved cash flow positivity and an MRD Adjusted EBITDA of $7.0M. Company Adjusted EBITDA was $28.0M. Cash and marketable securities were $216.8M. Company raised full-year MRD guidance to $202–$207M and narrowed operating spend and cash burn guidance.

Adaptive Biotechnologies (Nasdaq: ADPT) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors web page at www.adaptivebiotech.com, and the webcast will be archived and available for replay within 24 hours.

Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.

Management will engage in a fireside chat on September 10th at 1:05 PM ET. Investors can access both live and archived webcasts of the presentation through the company's website investor section at adaptivebiotech.com.

Adaptive Biotechnologies (Nasdaq: ADPT) reported strong Q2 2025 financial results, with total revenue reaching $58.9 million, a 36% year-over-year increase. The company's MRD business, contributing 85% of revenue, achieved profitability with $1.9 million in Adjusted EBITDA and 42% growth to $49.9 million.

Key highlights include 37% growth in clonoSEQ test volume to 25,321 tests, integration with Flatiron's OncoEMR platform, and implementation of NovaSeq X Plus for clinical sequencing. The company raised its 2025 MRD revenue guidance to $190-200 million and reduced cash burn guidance to $45-55 million.

Despite progress, the company reported a net loss of $25.6 million, though improved from $46.2 million in Q2 2024. Cash position remains strong at $222.0 million as of June 30, 2025.